News & Events January

CTI Clinical Trial and Consulting Services Announces Initiation of a Phase I/II Clinical Trial for Quark Pharmaceutical’s Systemically-Administered siRNA Drug Candidate, QPI-1007, for Delayed Graft Function

January 26, 2009

CTI Clinical Trial and Consulting Services (CTI) announces the initiation of patient dosing in a Phase I/II clinical trial evaluating Quark Pharmaceutical’s siRNA drug candidate QPI-1002 (also referred to as DGFi and I5NP) for the prophylaxis of delayed graft function (DGF) in patients undergoing deceased donor kidney transplantation. The ...

Read More

Subscribe to our mailing list

* indicates required